CoChat

A RANDOMIZED CONTROLLED TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR TREATMENT REFRACTORY INTERSTITIAL CYSTITIS

MAYER, ROBERT, PROPERT, KATHLEEN JOY, PETERS, KENNETH M., PAYNE, CHRISTOPHER K., ZHANG, YAWEI, BURKS, DAVID, CULKIN, DANIEL J., DIOKNO, ANANIAS, HANNO, PHILIP, LANDIS, J.RICHARD, MADIGAN, ROSEMARY, MESSING, EDWARD M., NICKEL, J.CURTIS, SANT, GRANNUM R., WARREN, JOHN, WEIN, ALAN J., KUSEK, JOHN W., NYBERG, LEROY M., FOSTER, HARRIS E., THE INTERSTITIAL CYSTITIS CLINICAL TRIALS GROUP · 2005 · Journal of Urology
Cited by 134

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

PURPOSE: We compared intravesical bacillus Calmette-Guerin (BCG) to placebo instillations in patients with treatment refractory interstitial cystitis (IC). MATERIALS AND METHODS: Subjects who met the National Institutes of Health-National Institute for Diabetes and Digestive and Kidney Diseases criteria for IC, and reported at least moderate pain and frequency for a minimum of 6 months before study entry, were randomized to 6 weekly double-blinded intravesical instillations of either BCG or placebo, and then followed for a total of 34 weeks. The primary outcome was a patient reported global response assessment at week 34, supplemented with medications for IC during weeks 31 to 34. Secondary outcomes included a 24-hour voiding diary, pain, urgency, validated IC symptom indexes and adverse events. The target sample size was 260 participants, designed to detect a difference in response rates between placebo and BCG of 30% and 50%, respectively. RESULTS: A total of 265 participants were randomized and 17 (6%) patients withdrew from study. The response rates for the primary outcome were 12% for placebo and 21% for BCG (p = 0.062). Small improvements were observed for all secondary outcomes, some more so with BCG, but these differences were of borderline statistical significance. Although a large number of adverse events were reported in the BCG arm, there was no statistically significant difference between the treatment arms in overall adverse event rates. CONCLUSIONS: Although the BCG safety profile was acceptable, the response rate for the primary outcome was low. Effective medical treatment for patients with moderate to severe interstitial cystitis remains elusive.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ju.0000152337.82806.e8

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 134

Metadata

Authors
MAYER, R., PROPERT, K. J., PETERS, K. M., PAYNE, C. K., ZHANG, Y., BURKS, D., CULKIN, D. J., DIOKNO, A., HANNO, P., LANDIS, J. R., MADIGAN, R., MESSING, E. M., NICKEL, J. C., SANT, G. R., WARREN, J., WEIN, A. J., KUSEK, J. W., NYBERG, L. M., FOSTER, H. E., & THE INTERSTITIAL CYSTITIS CLINICAL TRIALS GROUP
Venue
Journal of Urology
Published
2005-04
Volume
173
Issue
4
Pages
1186-1191
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2161708871
Cited by
134
References
1
FWCI
16.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A RANDOMIZED CONTROLLED TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR TREATMENT REFRACTORY INTERSTITIAL CYSTITIS. https://app.cochat.ai/papers/10.1097/01.ju.0000152337.82806.e8
The paper
MAYER, R., PROPERT, K. J., PETERS, K. M., PAYNE, C. K., ZHANG, Y., BURKS, D., CULKIN, D. J., DIOKNO, A., HANNO, P., LANDIS, J. R., MADIGAN, R., MESSING, E. M., NICKEL, J. C., SANT, G. R., WARREN, J., WEIN, A. J., KUSEK, J. W., NYBERG, L. M., FOSTER, H. E., & THE INTERSTITIAL CYSTITIS CLINICAL TRIALS GROUP. (2005). A RANDOMIZED CONTROLLED TRIAL OF INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR TREATMENT REFRACTORY INTERSTITIAL CYSTITIS. Journal of Urology. https://doi.org/10.1097/01.ju.0000152337.82806.e8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.